Events & Media - BetaGlue

Events

JPMorgan Annual Healthcare Conference

San Francisco (CA), USA

Meet BetaGlue’s CEO, CFO and Head of Clinical Development

12-15 January 2026

Spectrum Conference

Miami (FL), USA

Meet BetaGlue’s CEO, CFO and Head of Clinical Development

15-17 January 2026

MioLive 2026

Rome, Italy

Meet BetaGlue’s Head of Clinical Development

20-22 January 2026

News

News Press

12/11/2025

MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

News Press

22/09/2025

BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer

News Press

27/05/2025

BetaGlue® Announces ASCO Abstract Publication of the use of YntraDose® in an Advanced Large Animal Model of Pancreatic Cancer

News Press

20/02/2025

BetaGlue® Completes Exclusive Global Agreement With Artivion^TM Securing Supply Of BioGlue® For The Manufacture Of BetaGlue’s YntraDose® Oncology Platform

News Press

16/12/2024

ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue® Therapeutics Bringing 2024 Funding Round Total to €24m

News Press

06/06/2024

BetaGlue® Adds €8m Equity Financing to €10m EIC Accelerator Award

News Press

15/05/2024

BetaGlue® Therapeutics Announces the Appointment of Mike Cogswell as Chairman and Mike Maszy as Non-Executive Director

News Press

30/04/2024

BetaGlue® Technologies SpA Announces Rebrand & Introduces YntraDose®

News Press

04/03/2024

BetaGlue® Secures €10m EIC Accelerator Award

News Press

15/01/2024

BetaGlue® Appoints Salvatore Calabrese as Chief Financial Officer

News Press

27/02/2023

BetaGlue® renews the BoD: Dr Colin Story appointed CEO

News

20/10/2022